Logo

Lynx Therapeutics, Genome Institute of Singapore Engage in Transcriptome Study

Mar 05, 2003

NEW YORK, March 5 -- Lynx Therapeutics and the Genome Institute of the National University of Singapore today announced a research agreement on a comparative transcriptome study.

 

The Hayward, Calif., company will use its MPSS (massively parallel signature sequencing) technology to generate gene expression profiles from matched samples from human, mouse, and fish tissues. Financial details were not disclosed.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.